Japan · Series C startup

Who invested in Hirosaki Lifescience Innovation

One round we have observed, with the 2 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Healthcare

Funding summaryUpdated 26 Oct 2026

$15Mraised across 1 round since 2024, from 1 source

Latest round
Series C, $15MJul 2024
Investors
2
See who backed them

The rounds

  1. Jul 2024

Founders and team

From Hirosaki Lifescience Innovation's own website: 2 on the team.

  • Gregory D. Kunstグレゴリー・D・クンスト氏は、20年以上にわたりバイオ医薬品業界でリーダーシップを発揮してきた経験を有し、現在はValitor社の最高経営責任者(CEO)を務める
  • Matthew Fowlerファウラー氏は、資本政策、ipo準備、ベンチャー企業の経営指導に精通した経験豊富な金融戦略家であり、米国バイオテクノロジー企業のcfoである。

Everyone who backed them

Nippon Venture CapitalCorporate VC1round

Missing a round, or an investor who was in one? Tell us.

Quick answers about Hirosaki Lifescience Innovation

Who invested in Hirosaki Lifescience Innovation?

Hirosaki Lifescience Innovation's investors include Mitsubishi UFJ Capital and Nippon Venture Capital.

How much has Hirosaki Lifescience Innovation raised?

Hirosaki Lifescience Innovation has raised $15M across 1 round since 2024.

When did Hirosaki Lifescience Innovation last raise?

Hirosaki Lifescience Innovation's most recent round was a Series C of $15M in Jul 2024.

What was Hirosaki Lifescience Innovation's biggest round?

Its most recent round, $15M in Jul 2024, is also its largest on record.

Who backed Hirosaki Lifescience Innovation first?

Hirosaki Lifescience Innovation's first round on record, in Jul 2024, was backed by Mitsubishi UFJ Capital and Nippon Venture Capital.

What stage is Hirosaki Lifescience Innovation at?

Hirosaki Lifescience Innovation's latest named round is a Series C, in Jul 2024.

Where is Hirosaki Lifescience Innovation based?

Hirosaki Lifescience Innovation is based in Japan.

Companies like Hirosaki Lifescience Innovation

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.